NAMUR, Belgium, Oct. 30, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended September 30, 2015, the Company will host a conference call on November 4, 2015, at 8:30 a.m. United States Eastern Time.
Cameron Reynolds, Chief Executive Officer, will host the call and provide an update on recent developments including details of the ongoing clinical trials of the Company’s NuQ® blood-based diagnostic platform, progress on its ongoing trials, CE marks, patents and its market access strategy to support entry of its NuQ® colorectal cancer tests in the U.S. and Europe.
To participate in the call, please dial 1-888-452-4030 (toll-free) in the U.S. and Canada, and 1-719-457-2552 (toll) internationally. The conference ID number for both is 994675. A live audio webcast of the conference call will also be available via link on the investor relations page of VolitionRx’s corporate website at http://ir.volitionrx.com/.
After the live audio webcast, the event will remain archived on VolitionRx’s website for one year. In addition, a telephone replay of the call will be available until November 18, 2015. The replay dial-in numbers are 1-877-870-5176 (toll-free) in the U.S. and Canada and 1-858-384-5517 (toll) internationally. Please use replay pin number 994675.
About VolitionRx
VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid an indication that disease is present.
VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centered in Belgium as the Company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
Visit VolitionRx’s website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.
Media Contacts
Anita Heward, VolitionRx
a.heward@volitionrx.com
Telephone: +44 (0) 7756 034243
Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014
Investor Contacts
Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351
Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012
Safe Harbor Statement
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests” and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company’s bodily-fluid-based diagnostic tests as well as the Company’s ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company’s development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-schedules-third-quarter-2015-earnings-conference-call-and-business-update-for-wednesday-november-4-2015-at-830am-et-300169462.html
SOURCE VolitionRx Ltd
Help employers find you! Check out all the jobs and post your resume.
